Science:Life Sciences
On this week’s Biotech Hangout, guest Matt Gline, CEO of Roivant, joins hosts Daphne Zohar, Tim Opler, Mike Yee and Yaron Werber to discuss recent Phase 1 data from Immunovant, part of the Roivant family of companies & Igg degraders broadly (BHVN & ARGX). The hosts also cover biotech sentiment, M&A and the state of the XBI. They discuss BridgeBio PIPE funding, Alfasigma acquires Intercept Pharmaceuticals, setbacks for two CD47s (Abbvie and Gilead) and Morphic Therapeutic’s controversy. Other topics of discussion include Apellis Favus short report, and Bristol Myers Squibb and AstraZeneca drug pricing negotiations. *This episode aired on September 29, 2023*
More Episodes
Episode 57
2023-04-24
2023-04-24
Episode 56
2023-04-18
2023-04-18
Episode 55
2023-04-06
2023-04-06
Episode 54
2023-03-29
2023-03-29
Episode 53
2023-03-21
2023-03-21
Episode 52
2023-03-13
2023-03-13
Episode 51
2023-03-13
2023-03-13
Episode 50
2023-03-03
2023-03-03
Episode 49
2023-02-22
2023-02-22
Episode 48
2023-02-14
2023-02-14
Episode 47
2023-02-06
2023-02-06
Episode 46
2023-02-06
2023-02-06
Episode 45
2023-01-30
2023-01-30
Episode 44
2023-01-19
2023-01-19
Episode 43
2023-01-11
2023-01-11
Episode 42
2022-12-16
2022-12-16
Episode 41
2022-12-16
2022-12-16
Episode 40
2022-12-07
2022-12-07
Episode 39
2022-11-28
2022-11-28
Episode 38
2022-11-16
2022-11-16
Get this podcast on your
phone, FREE
